Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + LDAC vs Placebo + LDAC in Treatment-Naïve AML Patients Ineligible for Intensive Chemotherapy
NCT03069352Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of venetoclax in acute myeloid leukemia (AML), sponsored by AbbVie Inc.. Started May 2017; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03069352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03069352.